Abstract
The crystal structure of a recombinant form of the proteinase encoded by the feline immunodeficiency virus (FIV PR) has been solved at 2 Å resolution and refined to an R-factor of 0.148. The refined structure includes a peptidomimetic, statine-based inhibitor, LP-149, which is an even more potent inhibitor of HIV PR. Kinetic parameters were obtained for the cleavage of five substrates by FIV PR, and inhibition constants were measured for four inhibitors. The structure of FIV PR resembles other related retroviral enzymes although few inhibitors of HIV PR are capable of inhibiting FIV PR. The structure of FIV PR will enhance our knowledge of this class of enzymes, and will direct testing of new proteinase inhibitors in a feline animal model.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Temin, H.M. in The Retroviridae (ed. Levy, J.A.) 1–18 (Plenum Press, New York; 1992).
Fauci, A.S. The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 239, 617–622 (1988).
Jaskólski, M., Miller, M., Rao, J.K.M., Leis, J. & Wlodawer, A. Structure of the aspartic proteinase from Rous Sarcoma retrovirus refined at 2-Å resolution. Biochem. 29, 5889–5898 (1990).
Wlodawer, A. et al. Conserved folding in retroviral proteinases: Crystal structure of a synthetic HIV-1 proteinase. Science 245, 616–621 (1989).
Miller, M. et al. Structure of complex of synthetic HIV-1 proteinase with a substrate-based inhibitor at 2.3 Å resolution. Science 246, 1149–1152 (1989).
Wlodawer, A. & Erickson, J.W. Structure-based inhibitors of HIV-1 proteinase. A. Rev. Biochem. 62, 543–585 (1993).
Appelt, K. Crystal structures of HIV-1 proteinase-inhibitor complexes. Persp. in drug Discov. Design 1, 23–48 (1993).
Mulichak, A.M. et al. The crystallographic structure of the proteinase from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J. biol. Chem. 268, 13103–13109 (1993).
Tong, L., Pav, S., Pargellis, C., Do, F., Lamarre, D. & Anderson, P.C. Crystal structure of human immunodeficiency virus (HIV) type 2 proteinase in complex with a reduced amide inhibitor and comparison with HIV-1 proteinase structures. Proc. natn. Acad. Sci. U.S.A. 90, 8387–8391 (1993).
Zhao, B., Winborne, E., Minnich, M.D., Culp, J.S., Debouck, C. & Abdel-Meguid, S.S. Three-dimensional structure of a simian immunodeficiency virus proteinase/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 proteinase inhibitors. Biochemistry 32, 13054–13060 (1993).
Wilderspin, A.F. & Sugrue, R.J. Alternative native flap conformation revealed by 2.3 Å resolution structure of SIV proteinase. J. molec. Biol. 239, 97–103 (1994).
Pedersen, N.C. in: The Retroviridae (ed. Levy, J.A.) 181–228 (Plenum Press, New York; 1993).
Gardner, M.B. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 15, 267–286 (1991).
Farmerie, W.G., Goodenow, M.M. & Dunn, B.M., Cloning, expression and kinetic characterization of the feline immunodeficiency virus proteinase. Adv. exp. med. Biol. 306, 511–513 (1991).
Elder, J.H. et al. Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J. Virol. 67, 1869–1876 (1993).
Talbott, R.L. et al. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. natn. Acad. Sci. U.S.A. 86, 5743–5747 (1989).
Gustchina, A. in Aspartic Proteinases (ed. Takahashi, K.) (Plenum Publishing Corporation, New York; 1995).
Lin, Y. et al. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 proteinase: Relationship to drug resistance. Biochemistry 34, 1143–1152 (1995).
Andreeva, N.S. in Structure and Biosynthesis of Proteins (ed. Makarova, R.F.) 97–114 (Scientific Center for Biological Publishing, Pushchino; 1988).
Harte, W.E., Jr, Swaminathan, S., Mansuri, M.M., Martin, J.C., Rosenberg, I.E. & Beveridge, D.L. Domain communication in the dynamical structure of human immunodeficiency virus proteinase. Proc. natn. Acad. Sci. U.S.A. 87, 8864–8868 (1990).
Gustchina, A. & Weber, I.T. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10, 325–339 (1991).
Sardana, V.V. et al. Human immunodeficiency virus type 1 protease inhibitors: Evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33, 2004–2010 (1994).
Otto, M.J. et al. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 proteinase. Proc. natn. Acad. Sci. U.S.A. 90, 7543–7547 (1993).
Ho, D.D. et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric proteinase inhibitor. J. Virol. 68, 2016–2020 (1994).
Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple proteinase inhibitors. Nature 374, 569–571 (1995).
Griffiths, J.T. et al. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic* hydrophobic- or -aromatic* pro- cleavage sites. Biochemistry 31, 5193–5200 (1992).
Gellman, S.H. On the role of methionine residues in the sequence-independent recognition of nonpolar protein surfaces. Biochemistry 30, 6633–6636 (1991).
Thanki, N. et al. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Prot. Sci. 1, 1061–1072 (1992).
Hui, K.Y., Hermann, R.B., Manetta, J.V., Gygi, T. & Angleton, E.L. Model peptides to study the effects of P2 and P3 substitutions in statine-containing HIV proteinase inhibitors. FEBS Lett. 327, 355–360 (1993).
Dunn, B.M., Scarborough, P.E., Davenport, R. & Swienicki, W. in: Methods in Molecular Biology (ed. Dunn, B.M. & Pennington, M.W.) 225–243 (Humana Press, Totowa; 1994).
Brunger, A. X-PLOR: A System for X-Ray Crystallography and NMR. (Yale University Press, New Haven; 1992).
Furey, W. & Swaminathan, S. Phases-A program package for the processing and analysis of diffraction data for macromolecules. Ada crystallogr. (1990).
Hendrickson, W.A. Stereochemically restrained refinement of macromolecular structures. Meth. Enzymol. 115, 252–270 (1985).
Finzel, B.C. Incorporation of fast Fourier transforms to speed restrained least-squares refinement of protein structures. J. appl. Crystallogr. 20, 53–55 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wlodawer, A., Gustchina, A., Reshetnikova, L. et al. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Mol Biol 2, 480–488 (1995). https://doi.org/10.1038/nsb0695-480
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/nsb0695-480
This article is cited by
-
Biophysical characterization and crystal structure of the Feline Immunodeficiency Virus p15 matrix protein
Retrovirology (2013)
-
Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage
Pathology & Oncology Research (1997)


